Acute Oral Mucositis PainPhase 3NCT02229539
Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy
A Phase 3 study testing doxepin hydrochloride oral solution and DLA (diphenhydramine, lidocaine and antacids) rinse in people with Acute Oral Mucositis Pain, run by Alliance for Clinical Trials in Oncology at 350 sites in United States.
Trial summary
The purpose of this study is to test whether a mouthwash made with a drug called doxepin can reduce the pain caused by mouth sores resulting from radiation therapy. A number of mouth rinse preparations exist for patients with treatment-related oral mucositis pain such as the DLA rinse, an over-the-counter medication. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Oral Mucositis Pain
- What is being tested?
- doxepin hydrochloride oral solution and DLA (diphenhydramine, lidocaine and antacids) rinse
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 275 participants
- Where
- 350 sitesUnited States
- Study dates
- 18 Nov 2014to 15 Mar 2019
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
- Documentation of Disease: Histologic documentation of malignancy currently undergoing a course of RT (with or without chemotherapy) including the oral cavity and/or oropharyngeal area to a dose of at least 4500 cGy using more than 5 fractions (i.e., stereotactic body radiation therapy [SBRT] is not allowed).
- Physical exam demonstrating evidence of radiotherapy-related mucositis in the visible oral cavity and/or oropharynx consistent with mucous membrane toxicity greater than 0 using the Acute Radiation Morbidity Scoring Criteria.
- At least 4 (out of 10) patient-reported oral pain related to oral mucositis secondary to RT for which the patient seeks relief, as measured on the Oral Pain Assessment. Note: The pain score must be at least 4 at the time that the patient starts the first dose of study medication. The patient may be enrolled to the study if s/he, at times, has a pain score of at least 4, so long as initiation of study treatment begins when the pain score is at least 4.
- Ability to complete questionnaire(s) by themselves or with assistance.
- No known allergy to diphenhydramine, lidocaine, antacid (aluminum hydroxide, magnesium hydroxide, and simethicone), doxepin, tricyclic antidepressants, or any known component of the drug formulation in the testing arms.
- No use of any anti-arrhythmic medication (except for beta-blockers) including lidocaine, linezolid, ipratropium, or medications with high anti-cholinergic potency (including neostigmine, a tricyclic antidepressant or a monoamine oxidase inhibitor) within 2 weeks prior to registration.
- No current diagnosed untreated or unresolved oral candidiasis or oral HSV infection.
- No history of untreated narrow angle glaucoma within 6 weeks prior to registration.
- No untreated urinary retention within 6 weeks prior to registration.
- No current use of glutamine or sucralfate powders at the time of registration (no washout required).
- No cryotherapy for prophylactic mucosal protection within 6 weeks prior to registration.
- Not pregnant, because patients eligible for this study will be receiving radiotherapy, which has known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative pregnancy test done ≤ 28 days prior to registration is required.
- Age ≥ 18 years
- ECOG Performance Status 0, 1, or 2
Trial locations and contacts
350 sites in 1 country.
300 sites in 1 country
United States300 sites
Avera Saint Luke's Hospital and Cancer Center
Aberdeen, South Dakota, 57401
Providence Regional Cancer System-Aberdeen
Aberdeen, Washington, 98520
Cancer Care Center at Island Hospital
Anacortes, Washington, 98221
Anchorage Radiation Therapy Center
Anchorage, Alaska, 99504
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, 99508
Alaska Oncology and Hematology LLC
Anchorage, Alaska, 99508
Alaska Regional Hospital
Anchorage, Alaska, 99508
Alaska Women's Cancer Care
Anchorage, Alaska, 99508
Anchorage Oncology Centre
Anchorage, Alaska, 99508
Katmai Oncology Group
Anchorage, Alaska, 99508
Providence Alaska Medical Center
Anchorage, Alaska, 99508
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
Randolph Hospital
Asheboro, North Carolina, 27203
Rocky Mountain Cancer Centers-Aurora
Aurora, Colorado, 80012
The Medical Center of Aurora
Aurora, Colorado, 80012
Bronson Battle Creek
Battle Creek, Michigan, 49017
Beaufort Memorial Hospital
Beaufort, South Carolina, 29902
Swedish Cancer Institute-Eastside Oncology Hematology
Bellevue, Washington, 98005
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, 98225
Sanford Clinic North-Bemidji
Bemidji, Minnesota, 56601
Saint Charles Health System
Bend, Oregon, 97701
Constantinou, Costas L MD (UIA Investigator)
Bettendorf, Iowa, 52722
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Illinois CancerCare - Bloomington
Bloomington, Illinois, 61701
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Saint Luke's Mountain States Tumor Institute
Boise, Idaho, 83712
Central Care Center - Carrie J. Babb Cancer Center
Bolivar, Missouri, 65613
Parkland Health Center-Bonne Terre
Bonne Terre, Missouri, 63628
Boulder Community Hospital
Boulder, Colorado, 80301
Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado, 80304
Cox Cancer Center Branson
Branson, Missouri, 65616
Veterans Affairs Western New York Health Care System-Buffalo
Buffalo, New York, 14215
Roswell Park Cancer Institute
Buffalo, New York, 14263
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California, 91505
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Illinois CancerCare - Canton
Canton, Illinois, 61520
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
Mercy Hospital
Cedar Rapids, Iowa, 52403
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Centralia Oncology Clinic
Centralia, Illinois, 62801
Providence Regional Cancer System-Centralia
Centralia, Washington, 98531
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, 28204
Carolina Surgical Clinic of Charlotte PA
Charlotte, North Carolina, 28207
Oncology Specialists of Charlotte
Charlotte, North Carolina, 28207
Southern Oncology Specialists-Charlotte
Charlotte, North Carolina, 28262
Martha Jefferson Hospital
Charlottesville, Virginia, 22901
Cheyenne Regional Medical Center-West
Cheyenne, Wyoming, 82001
Marshfield Clinic-Chippewa Center
Chippewa Falls, Wisconsin, 54729
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Providence Oncology and Hematology Care Southeast
Clackamas, Oregon, 97015
Morton Plant Hospital
Clearwater, Florida, 33756
Southeastern Medical Oncology Center-Clinton
Clinton, North Carolina, 28328
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
Rocky Mountain Cancer Centers-Penrose
Colorado Springs, Colorado, 80907
Mercy Hospital
Coon Rapids, Minnesota, 55433
Bay Area Hospital
Coos Bay, Oregon, 97420
Geisinger Medical Center
Danville, Pennsylvania, 17822
Oakwood Hospital and Medical Center
Dearborn, Michigan, 48124
Cancer Care Specialists of Central Illinois
Decatur, Illinois, 62526
Decatur Memorial Hospital
Decatur, Illinois, 62526
Heartland Cancer Research NCORP
Decatur, Illinois, 62526
Porter Adventist Hospital
Denver, Colorado, 80210
Exempla Saint Joseph Hospital
Denver, Colorado, 80218
Presbyterian - Saint Lukes Medical Center - Health One
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Midtown
Denver, Colorado, 80218
Rocky Mountain Cancer Centers-Rose
Denver, Colorado, 80220
Rose Medical Center
Denver, Colorado, 80220
Colorado Blood Cancer Institute
Denver, Colorado, 80907
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates - Des Moines
Des Moines, Iowa, 50309
Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Saint John Hospital and Medical Center
Detroit, Michigan, 48236
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Epic Care-Dublin
Dublin, California, 94568
Mercy Medical Center
Durango, Colorado, 81301
Southwest Oncology PC
Durango, Colorado, 81301
Greenville Health System Cancer Institute-Easley
Easley, South Carolina, 29640
Marshfield Clinic Cancer Center at Sacred Heart
Eau Claire, Wisconsin, 54701
Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Fairview Southdale Hospital
Edina, Minnesota, 55435
Swedish Medical Center-Edmonds
Edmonds, Washington, 98026
Crossroads Cancer Center
Effingham, Illinois, 62401
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Bay Area Breast Surgeons Inc
Emeryville, California, 94608
Epic Care Partners in Cancer Care
Emeryville, California, 94608
Comprehensive Cancer Care and Research Institute of Colorado LLC
Englewood, California, 80113
Swedish Medical Center
Englewood, Colorado, 80110
Green Bay Oncology - Escanaba
Escanaba, Michigan, 49431
Illinois CancerCare - Eureka
Eureka, Illinois, 61530
Providence Regional Cancer Partnership
Everett, Washington, 98201
Sanford Clinic North-Fargo
Fargo, North Dakota, 58102
Sanford Medical Center-Fargo
Fargo, North Dakota, 58122
Sanford Roger Maris Cancer Center
Fargo, North Dakota, 58122
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
Saint Agnes Hospital/Agnesian Cancer Center
Fond du Lac, Wisconsin, 54935
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Unity Hospital
Fridley, Minnesota, 55432
Saint Luke's Mountain States Tumor Institute - Fruitland
Fruitland, Idaho, 83619
Gibbs Cancer Center-Gaffney
Gaffney, South Carolina, 29341
Illinois CancerCare - Galesburg
Galesburg, Illinois, 61401
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
CaroMont Regional Medical Center
Gastonia, North Carolina, 28054
Adams Cancer Center
Gettysburg, Pennsylvania, 17325
Mountain Blue Cancer Care Center
Golden, Colorado, 80401
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina, 27534
Wayne Memorial Hospital
Goldsboro, North Carolina, 27534
Altru Cancer Center
Grand Forks, North Dakota, 58201
Mercy Health Saint Mary's
Grand Rapids, Michigan, 49503
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
North Colorado Medical Center
Greeley, Colorado, 80631
Green Bay Oncology at Saint Vincent Hospital
Green Bay, Wisconsin, 54301
Saint Vincent Hospital
Green Bay, Wisconsin, 54301
Green Bay Oncology Limited at Saint Mary's Hospital
Green Bay, Wisconsin, 54303
Saint Mary's Hospital
Green Bay, Wisconsin, 54303
Cone Health Cancer Center
Greensboro, North Carolina, 27403
Greenville Health System Cancer Institute - Butternut
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Andrews
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Faris
Greenville, South Carolina, 29605
Greenville Memorial Hospital
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Eastside
Greenville, South Carolina, 29615
Rocky Mountain Cancer Centers-Greenwood Village
Greenwood Village, Colorado, 80111
Greenville Health System Cancer Institute-Greer
Greer, South Carolina, 29650
Gibbs Cancer Center-Pelham
Greer, South Carolina, 29651
Saint Francis Hospital and Medical Center
Hartford, Connecticut, 06105
Geisinger Medical Center-Cancer Center Hazelton
Hazleton, Pennsylvania, 18201
Comprehensive Cancer Centers of Nevada - Henderson
Henderson, Nevada, 89052
Las Vegas Cancer Center-Henderson
Henderson, Nevada, 89052
21st Century Oncology-Henderson
Henderson, Nevada, 89074
Comprehensive Cancer Centers of Nevada-Southeast Henderson
Henderson, Nevada, 89074
Hendersonville Hematology and Oncology at Pardee
Hendersonville, North Carolina, 28739
Margaret R Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida, 33021
Lake Norman Hematology Oncology Specialists-Huntersville
Huntersville, North Carolina, 28078
Southern Oncology Specialists-Huntersville
Huntersville, North Carolina, 28078
Lake Norman Hematology Oncology Specialists-Huntersville
Huntersville, North Carolina, 287078
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cancer Center of Kansas - Independence
Independence, Kansas, 67301
Green Bay Oncology - Iron Mountain
Iron Mountain, Michigan, 49801
Swedish Medical Center - Issaquah
Issaquah, Washington, 98029
Allegiance Health
Jackson, Michigan, 49201
Southeastern Medical Oncology Center-Jacksonville
Jacksonville, North Carolina, 28546
Capital Region Medical Center-Goldschmidt Cancer Center
Jefferson City, Missouri, 65109
Borgess Medical Center
Kalamazoo, Michigan, 49001
West Michigan Cancer Center
Kalamazoo, Michigan, 49007-3731
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Novant Health Oncology Specialists-Kernersville
Kernersville, North Carolina, 27284
Illinois CancerCare - Kewanee Clinic
Kewanee, Illinois, 61443
Cancer Center of Kansas - Kingman
Kingman, Kansas, 67068
Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin, 54601
Providence Regional Cancer System-Lacey
Lacey, Washington, 98503
Rocky Mountain Cancer Centers-Lakewood
Lakewood, Colorado, 80228
Saint Anthony Hospital
Lakewood, Colorado, 80228
Sparrow Hospital
Lansing, Michigan, 48912
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
Cancer and Blood Specialists-Henderson
Las Vegas, Nevada, 89106
Nevada Cancer Research Foundation NCORP
Las Vegas, Nevada, 89106
Radiation Oncology Centers of Nevada Central
Las Vegas, Nevada, 89106
21st Century Oncology
Las Vegas, Nevada, 89109
HealthCare Partners Medical Group Oncology/Hematology-Maryland Parkway
Las Vegas, Nevada, 89109
HealthCare Partners Medical Group Oncology/Hematology-San Martin
Las Vegas, Nevada, 89113
Radiation Oncology Centers of Nevada Southeast
Las Vegas, Nevada, 89119
Cancer Therapy and Integrative Medicine
Las Vegas, Nevada, 89121
21st Century Oncology-Vegas Tenaya
Las Vegas, Nevada, 89128
Cancer and Blood Specialists-Shadow
Las Vegas, Nevada, 89128
Cancer and Blood Specialists-Tenaya
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada, 89128
HealthCare Partners Medical Group Oncology/Hematology-Tenaya
Las Vegas, Nevada, 89128
Comprehensive Cancer Centers of Nevada-Summerlin
Las Vegas, Nevada, 89144
Las Vegas Cancer Center-Medical Center
Las Vegas, Nevada, 89148-2405
21st Century Oncology-Fort Apache
Las Vegas, Nevada, 89148
Cancer and Blood Specialists-Fort Apache
Las Vegas, Nevada, 89148
HealthCare Partners Medical Group Oncology/Hematology-Centennial Hills
Las Vegas, Nevada, 89149
Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada, 89169
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89169
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Lewistown Hospital
Lewistown, Pennsylvania, 17044
Novant Health Oncology Specialists-Davidson County
Lexington, North Carolina, 27295
Cancer Center of Kansas - Liberal
Liberal, Kansas, 67901
Rocky Mountain Cancer Centers-Littleton
Littleton, Colorado, 80120
Littleton Adventist Hospital
Littleton, Colorado, 80122
Saint Mary Mercy Hospital
Livonia, Michigan, 48154
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree, Colorado, 80124
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Longmont United Hospital
Longmont, Colorado, 80501
Rocky Mountain Cancer Centers-Longmont
Longmont, Colorado, 80501
Saint John Medical Center
Longview, Washington, 98632
McKee Medical Center
Loveland, Colorado, 80539
Illinois CancerCare - Macomb
Macomb, Illinois, 61455
Holy Family Memorial Hospital
Manitowoc, Wisconsin, 54221
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Bay Area Medical Center
Marinette, Wisconsin, 54143
Marshfield Clinic
Marshfield, Wisconsin, 54449
Saint Joseph's Hospital
Marshfield, Wisconsin, 54449
Contra Costa Regional Medical Center
Martinez, California, 94553-3156
Matthews Radiation Oncology Center
Matthews, North Carolina, 28105
Novant Health Cancer Specialists-Matthews
Matthews, North Carolina, 28105
Saint Luke's Mountain States Tumor Institute - Meridian
Meridian, Idaho, 83642
Mount Sinai Medical Center
Miami Beach, Florida, 33140
Middlesex Hospital
Middletown, Connecticut, 06457
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Health Partners Inc
Minneapolis, Minnesota, 55454
Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin, 54548
Memorial Regional Cancer Center Day Road
Mishawaka, Indiana, 46544
Garneau, Stewart C MD (UIA Investigator)
Moline, Illinois, 61265
Spector, David MD (UIA Investigator)
Moline, Illinois, 61265
Trinity Medical Center
Moline, Illinois, 61265
Lake Norman Hematology Oncology Specialists-Mooresville
Mooresville, North Carolina, 28117
Novant Health Oncology Specialists-Mount Airy
Mount Airy, North Carolina, 27030
Mercy Health Mercy Campus
Muskegon, Michigan, 49444
Saint Luke's Mountain States Tumor Institute - Nampa
Nampa, Idaho, 83686
North Shore-LIJ Health System/Center for Advanced Medicine
New Hyde Park, New York, 11040
Westfields Hospital/Cancer Center of Western Wisconsin
New Richmond, Wisconsin, 54017
New Ulm Medical Center
New Ulm, Minnesota, 56073
Providence Newberg Medical Center
Newberg, Oregon, 97132
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
Lakeland Community Hospital
Niles, Michigan, 49120
Alta Bates Summit Medical Center - Summit Campus
Oakland, California, 94609
Bay Area Tumor Institute CCOP
Oakland, California, 94609
Hematology and Oncology Associates-Oakland
Oakland, California, 94609
Green Bay Oncology - Oconto Falls
Oconto Falls, Wisconsin, 54154
Mercy Hospital Oklahoma City
Oklahoma City, Oklahoma, 73120
Providence Willamette Falls Medical Center
Oregon City, Oregon, 97045
Illinois CancerCare- Ottawa Clinic
Ottawa, Illinois, 61350
Radiation Oncology of Northern Illinois
Ottawa, Illinois, 61350
Parker Adventist Hospital
Parker, Colorado, 80138
Rocky Mountain Cancer Centers-Parker
Parker, Colorado, 80138
Cancer Center of Kansas - Parsons
Parsons, Kansas, 67357
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
Pekin Cancer Treatment Center
Pekin, Illinois, 61554
Memorial Hospital West
Pembroke Pines, Florida, 33028
Methodist Medical Center of Illinois
Peoria, Illinois, 61603
OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC
Peoria, Illinois, 61615-7827
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
OSF St. Francis Medical Center
Peoria, Illinois, 61637
Illinois CancerCare-Peru
Peru, Illinois, 61354
Valley Radiation Oncology
Peru, Illinois, 61354
FirstHealth of the Carolinas-Moore Regional Hospital
Pinehurst, North Carolina, 28374
Saint Joseph Mercy Oakland
Pontiac, Michigan, 48341
Saint Joseph Mercy Port Huron
Port Huron, Michigan, 48060
Maine Medical Center - Bramhall Campus
Portland, Maine, 04102
Providence Portland Medical Center
Portland, Oregon, 97213
Providence Saint Vincent Medical Center
Portland, Oregon, 97225
Geisinger Medical Oncology-Pottsville
Pottsville, Pennsylvania, 17901
Cancer Center of Kansas - Pratt
Pratt, Kansas, 67124
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Saint Mary Corwin Medical Center
Pueblo, Colorado, 81004
Rocky Mountain Cancer Centers - Pueblo
Pueblo, Colorado, 81008
Spectrum Health Reed City Hospital
Reed City, Michigan, 49677
Annie Penn Memorial Hospital
Reidsville, North Carolina, 27320
Marshfield Clinic at James Beck Cancer Center
Rhinelander, Wisconsin, 54501
Marshfield Clinic-Rice Lake Center
Rice Lake, Wisconsin, 54868
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Mayo Clinic
Rochester, Minnesota, 55905
OSF Saint Anthony Medical Center
Rockford, Illinois, 61108
Mercy Clinic-Rolla-Cancer and Hematology
Rolla, Missouri, 65401
Phelps County Regional Medical Center
Rolla, Missouri, 65401
William Beaumont Hospital - Royal Oak
Royal Oak, Michigan, 48073
Saint Mary's of Michigan
Saginaw, Michigan, 48601
Lakeland Hospital
Saint Joseph, Michigan, 49085
Marie Yeager Cancer Center
Saint Joseph, Michigan, 49085
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Regions Hospital
Saint Paul, Minnesota, 55101
United Hospital
Saint Paul, Minnesota, 55102
Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri, 63670
Cancer Center of Kansas - Salina
Salina, Kansas, 67401
Carolina Oncology Associates PA
Salisbury, North Carolina, 28144
Minor and James Medical PLLC
Seattle, Washington, 98104
Pacific Gynecology Specialists
Seattle, Washington, 98104
Swedish Medical Center-Ballard Campus
Seattle, Washington, 98107
Group Health Cooperative-Seattle
Seattle, Washington, 98112
Swedish Medical Center-First Hill
Seattle, Washington, 98122
Greenville Health System Cancer Institute-Seneca
Seneca, South Carolina, 29672
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
Saint Nicholas Hospital
Sheboygan, Wisconsin, 53081
Providence Regional Cancer System-Shelton
Shelton, Washington, 98548
Siouxland Regional Cancer Center
Sioux City, Iowa, 51101
Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota, 57104
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, 57117
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Spartanburg Medical Center
Spartanburg, South Carolina, 29303
Greenville Health System Cancer Institute-Spartanburg
Spartanburg, South Carolina, 29307
Rockwood Cancer Treatment Center-DHEC-Downtown
Spokane, Washington, 99204
Evergreen Hematology and Oncology PS
Spokane, Washington, 99218
Rockwood Clinic Cancer Treatment Center-Valley
Spokane Valley, Washington, 99216
Central Illinois Hematology Oncology Center
Springfield, Illinois, 62702
Springfield Clinic
Springfield, Illinois, 62703
Memorial Medical Center
Springfield, Illinois, 62781-0001
Cancer Research for the Ozarks NCORP
Springfield, Missouri, 65804
Mercy Hospital Springfield
Springfield, Missouri, 65804
Cox Health South Hospital
Springfield, Missouri, 65807
Saint Louis Cancer and Breast Institute - South City
St Louis, Missouri, 63109
About this study
Official title: A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy
The purpose of this study is to test whether a mouthwash made with a drug called doxepin can reduce the pain caused by mouth sores resulting from radiation therapy. A number of mouth rinse preparations exist for patients with treatment-related oral mucositis pain such as the DLA rinse, an over-the-counter medication. This study will evaluate the effects of doxepin compared to DLA (diphenhydramine, lidocaine and antacids) and placebo.Doxepin is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety, long-term pain management, as well as management of rash.
Read the detailed description
Patients are stratified according to sex (male vs. female), concurrent use of chemotherapy (no vs. yes), patient age at registration (< 60 years old vs. ≥ 60 years old and RTOG acute radiation morbidity criteria (1 vs. 2 vs 3 or more). Protocol therapy will consist of 2 cycles. Patients are randomized to one of three treatment regimens, which include doxepin, DLA and placebo. Cycle One will consist of one day. The care provider or nurse will confirm that the oral pain is at least 4 out of 10 severity level at the time of the rinse on the first day of the study. Patient will be asked to complete the baseline evaluation in the Oral Symptoms booklet. If the pain score is less than 4 then administration will be delayed until the pain is at least 4. Cycle Two will consist of an optional continuation phase lasting up to 7 days. Initiation of the Cycle 2/Continuation Phase may be delayed up to one week after Cycle 1/Day 1.
Primary Objective:
- Determine whether the doxepin rinse or DLA rinse is more effective than placebo in reducing OM-related pain in patients undergoing RT to the oral cavity, as measured by a patient-reported questionnaire at baseline, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, and 4 hours.
Secondary Objectives:
- Assess the adverse event profile of the doxepin rinse, the DLA rinse agent, and the placebo using a patient-reported questionnaire at 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, and 4 hours for domains of unpleasant taste, burning or stinging discomfort, and drowsiness.
- Compare the incidence of using additional analgesics between 1 and 4 hours after the initial mouthwash, between the doxepin oral rinse, the DLA rinse agent, and the placebo arms.
- Compare the length of time that each study product is used by patients in the one-week continuation phase.
- Compare the daily pain scores in the one-week continuation phase for the three study arms.
- Compare the 24-hour morphine equivalent dose used in the continuation phase for the three study arms.
- Conditions
- Acute Oral Mucositis Pain
- Being tested
- doxepin hydrochloride oral solution, DLA (diphenhydramine, lidocaine and antacids) rinse, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
doxepin hydrochloride oral solutionDrug
2.5 mL (25 mg) doxepin and 2.5 mL water administered orally
DLA (diphenhydramine, lidocaine and antacids) rinseDrug
5.0 mL administered orally
PlaceboOther
2.5 mL placebo and 2.5 mL water administered orally
| Study group | Role | What they receive |
|---|---|---|
| doxepin rinse | Experimental | Patients receive 2.5 mL (25 mg) doxepin and 2.5 mL water orally. Doxepin rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.
Patients will complete the Oral Symptoms booklet per the protocol. Receives: Drug: doxepin hydrochloride oral solution |
| DLA (diphenhydramine, lidocaine and antacid) rinse | Active comparator | Patients receive 5.0 mL DLA orally. DLA is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients receiving DLA during the continuation phase of the study, they and/or caregivers may be aware that they are receiving DLA.
Patients will complete the Oral Symptoms booklet per the protocol. Receives: Drug: DLA (diphenhydramine, lidocaine and antacids) rinse |
| placebo rinse | Placebo comparator | Patients receive 2.5 mL placebo and 2.5 mL water orally. The placebo rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment.
Patients will complete the Oral Symptoms booklet per the protocol. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Area Under the Curve (AUC) of Total Pain Reduction
Total pain reduction (mouth and throat) was measured by the numerical analogue scale of mouth pain on a scale of 0 to 10, with 0=no pain and 10=worst pain in the questionnaires taken at baseline, and 5, 15, 30, 60, 120, 240 minutes after assigned treatment for doxepin or DLA vs. placebo. The total pain reduction was calculated by the (average of mouth and throat) area under the curve (AUC) adjusting for baseline, with time scale (baseline, 5, 15, 30, 60, 120 and 240 minutes post treatment) replaced by a numerical scale of 0, 1, 2, 3, 4, 5 and 6 respectively. The AUC was prorated when there are terminal missing data. If the missing data were intermittent, simple imputation by trapezoidal rules were applied to calculate the AUC. If a patient cancelled, was missing baseline data, or only provided baseline data, he/she was excluded from the statistical analysis.
Measured: Baseline, 5, 15, 30, 60, 120, 240 minutes post treatment
Secondary outcomes (8)
Area Under the Curve (AUC) of Total Unpleasant Taste of the Oral Rinse
Total unpleasant taste was measured by the numerical analogue scale of taste of the oral rinse on a scale of 0 to 10, with 0=acceptable and 10=terrible in the questionnaires taken at 5, 15, 30, 60, 120, 240 minutes after assigned treatment for doxepin or DLA vs. placebo. The total unpleasant taste was calculated by the area under the curve (AUC) adjusting for 5 minutes post treatment, with time scale (5, 15, 30, 60, 120 and 240 minutes post treatment) replaced by a numerical scale of 1, 2, 3, 4 5 and 6 respectively. The AUC was prorated when there are terminal missing data. If the missing data were intermittent, simple imputation by trapezoidal rules were applied to calculate the AUC. If a patient cancelled, was missing 5 minutes after treatment data, or only provided 5 minutes after treatment data, he/she was excluded from the statistical analysis.
Measured: 5, 15, 30, 60, 120, 240 minutes post treatment
Area Under the Curve (AUC) of Total Stinging or Burning From the Oral Rinse
Total stinging or burning was measured by the numerical analogue scale of stinging or burning from the oral rinse on a scale of 0 to 10, with 0=no stinging or burning and 10=worst stinging or burning possible in the questionnaires taken at 5, 15, 30, 60, 120, 240 minutes after assigned treatment for doxepin or DLA vs. placebo. The total stinging or burning was calculated by the area under the curve (AUC) adjusting for 5 minutes post treatment, with time scale (5, 15, 30, 60, 120 and 240 minutes post treatment) replaced by a numerical scale of 1, 2, 3, 4 5 and 6 respectively. The AUC was prorated when there are terminal missing data. If the missing data were intermittent, simple imputation by trapezoidal rules were applied to calculate the AUC. If a patient cancelled, was missing 5 minutes after treatment data, or only provided 5 minutes after treatment data, he/she was excluded from the statistical analysis.
Measured: 5, 15, 30, 60, 120, 240 minutes post treatment
Area Under the Curve (AUC) of Total Drowsiness
Total drowsiness was measured by the numerical analogue scale of drowsiness on a scale of 0 to 10, with 0=no drowsiness and 10=extreme drowsiness, leading to sleep in the questionnaires taken at baseline, and 5, 15, 30, 60, 120, 240 minutes after assigned treatment for doxepin or DLA vs. placebo. The total drowsiness was calculated by the area under the curve (AUC) adjusting for baseline, with time scale (baseline, 5, 15, 30, 60, 120 and 240 minutes post treatment) replaced by a numerical scale of 0, 1, 2, 3, 4, 5 and 6 respectively. The AUC was prorated when there are terminal missing data. If the missing data were intermittent, simple imputation by trapezoidal rules were applied to calculate the AUC. If a patient cancelled, was missing baseline data, or only provided baseline data, he/she was excluded from the statistical analysis.
Measured: Baseline, 5, 15, 30, 60, 120, 240 minutes post treatment
The Incidence of Using Alternative Analgesics
Patients were asked if they have taken any other pain medications, if yes, to record the name, strength and when they have taken the pain medications in the 120 minutes and 240 minutes post treatment questionnaires.
Measured: At 120 and 240 minutes post treatment
Patient Preference for Continued Therapy With Oral Rinse After Initial Test Rinse Phase
Patients were asked: "Based on your experience with this current oral rinsing medication, would you want to take another dose now if it were available?" in the 240 minutes post treatment questionnaire.
Measured: At 240 minutes post treatment
Frequency of Study Rinse Used in the Continuation Phase
Patients were asked: "Did you use the study rinse today?" daily questionnaire during the optional continuation phase (Cycle 2).
Measured: Up to 7 days.
Median Mouth Pain Score in the Continuation Phase
Mouth pain scores was measured using the numerical analogue scale ranging from scale of 0 to 10, with 0=no pain and 10=worst pain daily during the optional continuation phase (Cycle 2).
Measured: Day 1 to Day 7 in the Continuation Phase
The Incidence of Using Alternative Analgesics in the Continuation Phase
Patients were asked if they have taken any medications for pain over the past 24 hours, if yes, to record the name, strength and when they have taken the pain medications daily during the optional continuation phase (Cycle 2).
Measured: Day 1 to Day 7 in the Continuation Phase
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Sep 2014 (estimated)
- Study start18 Nov 2014
- Primary completion23 May 2016
- Study completion15 Mar 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Acute Oral Mucositis PainStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 275 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Robert Miller, MD, MS, Study chair, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02229539
- Sponsor's protocol ID
- A221304
- Other IDs
- U10CA037447, UG1CA189823, NCI-2014-01877
- Status last verified
- May 2025
- First submitted
- 29 Aug 2014
- Last updated
- 18 May 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Sio TT, Le-Rademacher JG, Leenstra JL, Loprinzi CL, Rine G, Curtis A, Singh AK, Martenson JA Jr, Novotny PJ, Tan AD, Qin R, Ko SJ, Reiter PL, Miller RC. Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial. JAMA. 2019 Apr 16;321(15):1481-1490. doi: 10.1001/jama.2019.3504.
PubMed 30990550
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy
- ClinicalTrials.gov ID
- NCT02229539
- Acronym / sponsor ID
- A221304
- Conditions
- Acute Oral Mucositis Pain
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 275 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 18 Nov 2014 (actual)
- Primary completion
- 23 May 2016 (actual)
- Study completion
- 15 Mar 2019 (actual)
- First posted
- 1 Sep 2014 (estimated)
- Results
- Posted 10 Apr 2017
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to test whether a mouthwash made with a drug called doxepin can reduce the pain caused by mouth sores resulting from radiation therapy. A number of mouth rinse preparations exist for patients with treatment-related oral mucositis pain such as the DLA rinse, an over-the-counter medication. This study will evaluate the effects of doxepin compared to DLA (diphenhydramine, lidocaine and antacids) and placebo.Doxepin is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety, long-term pain management, as well as management of rash.
Detailed description
Patients are stratified according to sex (male vs. female), concurrent use of chemotherapy (no vs. yes), patient age at registration (< 60 years old vs. ≥ 60 years old and RTOG acute radiation morbidity criteria (1 vs. 2 vs 3 or more). Protocol therapy will consist of 2 cycles. Patients are randomized to one of three treatment regimens, which include doxepin, DLA and placebo. Cycle One will consist of one day. The care provider or nurse will confirm that the oral pain is at least 4 out of 10 severity level at the time of the rinse on the first day of the study. Patient will be asked to complete the baseline evaluation in the Oral Symptoms booklet. If the pain score is less than 4 then administration will be delayed until the pain is at least 4. Cycle Two will consist of an optional continuation phase lasting up to 7 days. Initiation of the Cycle 2/Continuation Phase may be delayed up to one week after Cycle 1/Day 1.
Primary Objective:
- Determine whether the doxepin rinse or DLA rinse is more effective than placebo in reducing OM-related pain in patients undergoing RT to the oral cavity, as measured by a patient-reported questionnaire at baseline, 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, and 4 hours.
Secondary Objectives:
- Assess the adverse event profile of the doxepin rinse, the DLA rinse agent, and the placebo using a patient-reported questionnaire at 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, and 4 hours for domains of unpleasant taste, burning or stinging discomfort, and drowsiness.
- Compare the incidence of using additional analgesics between 1 and 4 hours after the initial mouthwash, between the doxepin oral rinse, the DLA rinse agent, and the placebo arms.
- Compare the length of time that each study product is used by patients in the one-week continuation phase.
- Compare the daily pain scores in the one-week continuation phase for the three study arms.
- Compare the 24-hour morphine equivalent dose used in the continuation phase for the three study arms.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| doxepin rinse | Experimental | Drug: doxepin hydrochloride oral solutionPatients receive 2.5 mL (25 mg) doxepin and 2.5 mL water orally. Doxepin rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment. Patients will complete the Oral Symptoms booklet per the protocol. |
| DLA (diphenhydramine, lidocaine and antacid) rinse | Active comparator | Drug: DLA (diphenhydramine, lidocaine and antacids) rinsePatients receive 5.0 mL DLA orally. DLA is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients receiving DLA during the continuation phase of the study, they and/or caregivers may be aware that they are receiving DLA. Patients will complete the Oral Symptoms booklet per the protocol. |
| placebo rinse | Placebo comparator | Other: PlaceboPatients receive 2.5 mL placebo and 2.5 mL water orally. The placebo rinse is administered in the clinic on Day 1 (Cycle 1). There is an optional continuation phase within seven days following Day 1 (Cycle 1), patients will be encouraged to continue treatment with the study agent for an additional week (Cycle 2) where the patient takes the rinse at home every 4 hours. Chemotherapy is allowed during the continuation phase. Patients randomized to doxepin or placebo, they and their caregivers will continue to be blinded to the treatment. Patients will complete the Oral Symptoms booklet per the protocol. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| doxepin hydrochloride oral solution2.5 mL (25 mg) doxepin and 2.5 mL water administered orally | Drug | doxepin rinse |
| DLA (diphenhydramine, lidocaine and antacids) rinse5.0 mL administered orally | Drug | DLA (diphenhydramine, lidocaine and antacid) rinse |
| Placebo2.5 mL placebo and 2.5 mL water administered orally | Other | placebo rinse |
Primary outcome
Mean Area Under the Curve (AUC) of Total Pain Reduction
Time frame: Baseline, 5, 15, 30, 60, 120, 240 minutes post treatment
Total pain reduction (mouth and throat) was measured by the numerical analogue scale of mouth pain on a scale of 0 to 10, with 0=no pain and 10=worst pain in the questionnaires taken at baseline, and 5, 15, 30, 60, 120, 240 minutes after assigned treatment for doxepin or DLA vs. placebo. The total pain reduction was calculated by the (average of mouth and throat) area under the curve (AUC) adjusting for baseline, with time scale (baseline, 5, 15, 30, 60, 120 and 240 minutes post treatment) replaced by a numerical scale of 0, 1, 2, 3, 4, 5 and 6 respectively. The AUC was prorated when there are terminal missing data. If the missing data were intermittent, simple imputation by trapezoidal rules were applied to calculate the AUC. If a patient cancelled, was missing baseline data, or only provided baseline data, he/she was excluded from the statistical analysis.
8 secondary outcomes
Area Under the Curve (AUC) of Total Unpleasant Taste of the Oral Rinse
Time frame: 5, 15, 30, 60, 120, 240 minutes post treatment
Area Under the Curve (AUC) of Total Stinging or Burning From the Oral Rinse
Time frame: 5, 15, 30, 60, 120, 240 minutes post treatment
Area Under the Curve (AUC) of Total Drowsiness
Time frame: Baseline, 5, 15, 30, 60, 120, 240 minutes post treatment
The Incidence of Using Alternative Analgesics
Time frame: At 120 and 240 minutes post treatment
Patient Preference for Continued Therapy With Oral Rinse After Initial Test Rinse Phase
Time frame: At 240 minutes post treatment
Frequency of Study Rinse Used in the Continuation Phase
Time frame: Up to 7 days.
Median Mouth Pain Score in the Continuation Phase
Time frame: Day 1 to Day 7 in the Continuation Phase
The Incidence of Using Alternative Analgesics in the Continuation Phase
Time frame: Day 1 to Day 7 in the Continuation Phase
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 30990550Sio TT, Le-Rademacher JG, Leenstra JL, Loprinzi CL, Rine G, Curtis A, Singh AK, Martenson JA Jr, Novotny PJ, Tan AD, Qin R, Ko SJ, Reiter PL, Miller RC. Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial. JAMA. 2019 Apr 16;321(15):1481-1490. doi: 10.1001/jama.2019.3504.
Related trials for Acute Oral Mucositis Pain
Recruiting
Effectiveness of Hydrogen Water Intervention on Acute Oral Inflammation, Oral Microbiota, and Pain Following Free Flap Reconstruction in Patients With Oral Cancer
Oral Squamous Cell Carcinoma (OSCC), Postoperative Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robert Miller, MD, MS study chair
Mayo Clinic
350 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing doxepin hydrochloride oral solution and DLA (diphenhydramine, lidocaine and antacids) rinse in people with Acute Oral Mucositis Pain, run by Alliance for Clinical Trials in Oncology at 350 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 350 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Apr 2017). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Area Under the Curve (AUC) of Total Pain Reduction (time frame: Baseline, 5, 15, 30, 60, 120, 240 minutes post treatment). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02229539, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2025.